Published in Lancet Neurol on December 30, 2014
Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy (E-SCAR DMD) | NCT01521546
Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation (2015) 1.55
Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc (2015) 1.00
Cardiac involvement in Duchenne and Becker muscular dystrophy. World J Cardiol (2015) 0.87
Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat (2016) 0.83
The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy. J Neuromuscul Dis (2015) 0.81
Duchenne Muscular Dystrophy Mice and Men: Can Understanding a Genetic Cardiomyopathy Inform Treatment of Other Myocardial Diseases? Circ Res (2016) 0.80
Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J (2015) 0.80
Ambulatory Monitoring and Arrhythmic Outcomes in Pediatric and Adolescent Patients With Duchenne Muscular Dystrophy. J Am Heart Assoc (2015) 0.79
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. PLoS One (2015) 0.79
Cardiomyopathy in Muscular Dystrophy: When to Treat? JAMA Cardiol (2016) 0.78
Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice. J Neuromuscul Dis (2016) 0.77
Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice. Sci Rep (2015) 0.76
SIRT1: A Novel Target for the Treatment of Muscular Dystrophies. Oxid Med Cell Longev (2016) 0.75
Cardiomyopathy in becker muscular dystrophy: Overview. World J Cardiol (2016) 0.75
Myocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers. J Cardiovasc Magn Reson (2016) 0.75
Glucocorticoid therapy for Duchenne cardiomyopathy: A Hobson's choice? J Am Heart Assoc (2015) 0.75
Rules of tissue packing involving different cell types: human muscle organization. Sci Rep (2017) 0.75
Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene expression profiles in dystrophic skeletal muscles. Am J Physiol Cell Physiol (2016) 0.75
Eplerenone repolarizes muscle membrane through Na,K-ATPase activation by Tyr10 dephosphorylation. Acta Myol (2016) 0.75
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial. Orphanet J Rare Dis (2017) 0.75
Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis (2017) 0.75
Prevention of cardiomyopathy in Duchenne muscular dystrophy. Lancet Neurol (2014) 0.75
Recent Advances in Understanding and Managing Cardiomyopathy. F1000Res (2017) 0.75
A De novo Mutation in Dystrophin Causing Muscular Dystrophy in a Female Patient. Chin Med J (Engl) (2017) 0.75
Implantation of a left ventricular assist device to provide long-term support for end-stage Duchenne muscular dystrophy-associated cardiomyopathy. ESC Heart Fail (2017) 0.75
Central Arterial Function Measured by Non-invasive Pulse Wave Analysis is Abnormal in Patients with Duchenne Muscular Dystrophy. Pediatr Cardiol (2017) 0.75
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform (2008) 71.12
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol (2002) 5.74
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA (2013) 5.19
Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation (2004) 4.23
Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol (2005) 3.64
Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc Imaging (2008) 2.96
Measuring and mapping cardiac fiber and laminar architecture using diffusion tensor MR imaging. Ann N Y Acad Sci (2005) 2.35
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J (2014) 2.13
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation (2011) 2.06
Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol (2009) 1.74
A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. Eur Heart J (2003) 1.52
Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging (2011) 1.47
Prognostic value of myocardial circumferential strain for incident heart failure and cardiovascular events in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J (2013) 1.32
Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging (2013) 1.29
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res (2003) 1.22
Cardiac assessment in duchenne and becker muscular dystrophies. Curr Heart Fail Rep (2010) 1.21
Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens (2008) 1.04
Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther (2011) 1.04
Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol (2014) 1.02
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PLoS One (2014) 1.01
Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol (2007) 1.01
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord (2011) 1.00
Osteopontin: a biomarker to predict the outcome of inflammatory heart disease. Semin Thromb Hemost (2010) 0.95
Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail (2013) 0.93
Myocardial inflammation in Duchenne Muscular Dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol (2010) 0.90
Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve (2009) 0.89
Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10. Hum Mol Genet (2014) 0.89
Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 0.88
The signaling pathway for aldosterone-induced mitochondrial production of superoxide anion in the myocardium. J Mol Cell Cardiol (2013) 0.83
Clinical applications for cardiovascular magnetic resonance imaging at 3 tesla. Curr Cardiol Rev (2009) 0.83
Fat embolism syndrome in patients with Duchenne muscular dystrophy. Neurology (2013) 0.80
Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values. Eur Heart J Cardiovasc Imaging (2015) 1.02
Regional circumferential strain is a biomarker for disease severity in duchenne muscular dystrophy heart disease: a cross-sectional study. Pediatr Cardiol (2014) 0.89
Feature-tracking cardiovascular magnetic resonance as a novel technique for the assessment of mechanical dyssynchrony. Int J Cardiol (2014) 0.82
A pilot study of target weight guided treatment in acute heart failure using ultrafiltration or usual care: effect on sodium removal. Korean Circ J (2014) 0.78
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial. Orphanet J Rare Dis (2017) 0.75
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol (2017) 0.75
Relationship of Right Ventricular Size and Function with Respiratory Status in Duchenne Muscular Dystrophy. Pediatr Cardiol (2016) 0.75
Erratum to: Relationship of Right Ventricular Size and Function with Respiratory Status in Duchenne Muscular Dystrophy. Pediatr Cardiol (2016) 0.75
Progression of Duchenne Cardiomyopathy Presenting with Chest Pain and Troponin Elevation. J Neuromuscul Dis (2017) 0.75
Clinical Issues and Controversies in Heart Failure and Transplantation. World J Pediatr Congenit Heart Surg (2016) 0.75
Comparison of right and left ventricular function and size in Duchenne muscular dystrophy. Eur J Radiol (2015) 0.75
Cardiac magnetic resonance tissue tracking in right ventricle: feasibility and normal values. Magn Reson Imaging (2017) 0.75